United States Patent (19) 11 Patent Number: 4,822,930 Liu 45 Date of Patent: Apr

Total Page:16

File Type:pdf, Size:1020Kb

United States Patent (19) 11 Patent Number: 4,822,930 Liu 45 Date of Patent: Apr United States Patent (19) 11 Patent Number: 4,822,930 Liu 45 Date of Patent: Apr. 18, 1989 (54) PROCESS FOR PREPARING 3,890,326 6/1975 Tobin .................................. 570/206 MONOBROMINATED CYCLOBUTARENES 4,540,763 9/1985 Kirchhoff............................ 526/281 (75) Inventor: Ming-Biann Liu, Midland, Mich. OTHER PUBLICATIONS (73) Assignee: The Dow Chemical Company, Lloyd et al., "The Electrophilic Substitution of Ben Midland, Mich. zocyclobutene-II', Tetrahedron, 1965, vol. 21, pp. 245 (21) Appl. No.: 64,714 to 254. Lloyd et al., "Tetrahedron', vol. 20, pp. 2184-2194 22) Filed: Jun. 22, 1987 (1964). (51) Int. Cl'....................... C07C21/24: CO7C 17/00 52 U.S. C. .................................... 570/206; 570/207; Primary Examiner-Werren B. Lone 570/208; 570/209; 570/211 57 ABSTRACT 58) Field of Search ............... 570/206, 207,208, 209, Monobrominated cyclobutarenes are prepared by bro 570/210 minating a cyclobutarene in the presence of an organic (56) References Cited complexing agent, an acid scavenger, or water. Faster U.S. PATENT DOCUMENTS reaction rates highly selective to monobrominated cy clobutarenes are obtained without conventional heavy 3,420,035 2/1969 Bremmer ............................. 570/206 metal or halogen catalysts. 3,607,883 9/1971 Schneider ........ ... 570/206 3,755,444 8/1973 Schneider et al. .................. 570/206 3,763,248 10/1973 Mitchell .............................. 570/206 32 Claims, No Drawings 4,822,930 1. 2 high performance monomeric and polymeric composi PROCESS FOR PREPARNG tions for the electronics industry. MONOBROMINATED CYCLOBUTARENES DETALED DESCRIPTION OF THE BACKGROUND OF THE INVENTION 5 INVENTION This invention relates to a process for preparing bro As the term is used herein, "cyclobutarene' refers to minated organic compounds. More specifically, it re a compound oontaining at least one aromatic ring to lates to a process for preparing monobrominated cy which is fused one or more cyclobutane rings or one or clobutarenes. more substituted cyclobutane rings. An aromatic ring Monobrominated cyclobutarenes are intermediates 10 contains (4N --2)n electrons as described in Morrison for the preparation of high performance monomeric and and Boyd, Organic Chemistry. 3rd Edition, (1973). Suit polymeric compositions for the electronics and aero able compounds containing at least one aromatic ring space industries. U.S. Pat. No. 4,540,763 discloses that include benzene, naphthalene, biphenyl, binaphthyl, monobrominated cyclobutarenes can be processed to phenanthrene, anthracene, and diphenylbenzene. The prepare poly(cyclobutarene) polymeric compositions. 15 aromatic ring of the cyclobutarene can be substituted These compositions possess thermal stability at high with groups stable to the bromination reaction, includ temperatures, as well as chemical resistance and low ing but not limited to groups such as methyl, methoxy, sensibility to water. and acetate. Heterocyclic compounds such as pyridine Processes for preparing monobrominated cyclobuta and picoline are also included. Preferred compounds renes are difficult because multiple bromination reac 20 are benzene, naphthalene, and biphenyl. The most pre tions occur and the strained cyclobutane ring of the ferred compound containing at least one aromatic ring cyclobutarene is easily susceptible to ring-opening side is benzene. Therefore, the most preferred cyclobutarene reactions (see J. B. F. Lloyd et al., Tetrahedron 20, pp. is benzocyclobutene. 2185-94 (1964)). U.S. Pat. No. 4,540,763 discloses a process for preparing monobrominated cyclobutarenes 25 As disclosed in U.S. Pat. No. 4,570,011, cyclobuta which involves diluting a cyclobutarene in acetic acid renes useful in this invention can be prepared by dis and then contacting the solution with pyridinium per solving an ortho alkyl halomethyl aromatic hydrocar bromide hydrobromide in the presence of a mercuric bon, such as ortho methylchloromethylbenzene, in an acetate catalyst. The reaction occurs over a four day inert solvent, and then pyrolyzing the solution under period and uses approximately 300 percent excess bro 30 suitable reaction conditions. minating agent. J. B. F. Lloyd et al., Tetrahedron, 21, pp. "Brominating” refers to the introduction of bromine 245-54, (1965), disclose a process for preparing mono into an organic compound by treating the compound brominated benzocyclobutene which involves diluting with a brominating agent. Suitable brominating agents benzocyolobutene in a 95 percent aqueous solution of useful in this invention are those compounds which are acetic acid and then contacting the solution with molec 35 capable of reacting with the aromatic ring of the cy ular bromine in the presence of an iodine catalyst. The clobutarene to break the carbonhydrogen bond and to yield of monobrominated benzocyclobutene is 78 per form a carbon-halogen bond under the reaction condi cent after 48 hours. Unfortunately, both of these pro tions. H. P. Braendlin et al. Friedel-Crafts and Related cesses require large quantities of brominating agent to Reactions. Vol. III, Chapter 46, pp. 1517-1593, John complete a very slow bromination reaction. Also, both Wiley & Sons, New York (1964), disclose brominating processes require either a heavy metal catalyst or a agents useful for brominating organic compounds. The halogen catalyst. The residual catalyst that inevitably brominating agents that can be employed in this inven finds its way into the final product is detrimental for tion can include molecular bromine, bromine chloride, electronics and aerospace industry applications. Fur pyridinium perbromide hydrobromide, dioxane dibro thermore, these catalysts create environmental prob 45 mide, and N-bromosuccinimide. Preferred brominating lems related to their disposal. agents include molecular bromine and bromine chlo Therefore, it would be desirable to have a process for ride. The most preferred brominating agent is molecular preparing monobrominated cyclobutarenes that does bromine. not require a halogen catalyst or a heavy metal catalyst. The monobrominated cyclobutarenes useful in this It would also be desirable to have a process providing a 50 invention are prepared by brominating a cyclobutarene. faster bromination reaction highly selective to mono The term "monobrominated” refers to the replacement brominated cyclobutarenes without requiring excessive of one hydrogen atom on the aromatic ring with one quantities of brominating agent. bromine atom. The products produced from the bromi SUMMARY OF THE INVENTION nation of the cyclobutarene include not only the mono 55 brominated cyclobutarenes but also small quantities of This invention is a method of preparing mono hydrogen bromide, unreacted brominating agent and brominated cyclobutarenes consisting essentially of undesirable side reaction products. The hydrogen bro brominating a cyclobutarene in the presence of an or mide can either dissolve in the reaction mixture or ganic complexing agent, an acid scavenger, or water. evolve from the reaction mixture as a gas. Surprisingly, reaction rates faster than the rates dis 60 The organic complexing agents that improve the closed in the prior art are achieved by the method of selectivity of the reaction to monobrominated cy this invention without requiring a catalyst. In addition, clobutarenes are organic compounds that will donate the reaction is highly selective to monobrominated electrons to form donor-acceptor adducts with the un cyclobutarenes and neither requires excessive quantities reacted brominating agent and the hydrogen bromide of brominating agent nor creates an environmental 65 produced during the reaction. The adduct formed re problem related to the disposal of the catalysts. duces the reactivity of the brominating agent and hy The monobrominated cyclobutarenes of this inven drogen bromide with the cyclobutane ring of the cy tion are useful as intermediates for the preparation of clobutarene and therefore reduces formation of undesir 4,822,930 3 4. able side products. A. J. Downs et al., Comprehensive metal and alkali earth metals, such as sodium bicarbon Inorganic Chemistry, Chapter 26, pp. 1196-1197 and pp. ate and potassium carbonate. 1201-1209, New York, New York, (1973), discuss the When the cyclobutarene is brominated in the pres crystalline structure of halogen adducts based on X-ray ence of water, the water acts in a manner similar to that diffraction studies. They describe organic compounds 5 of the organic complexing agent by forming donor which form halogen adducts and the factors influencing acceptor adducts with the unreacted brominating agent their stability. They also describe the relative capacities and the hydrogen bromide. of organic compounds to donate electrons. Preferably, In a preferred embodiment of this invention, the solu the organic complexing agent has an electron donor bility of hydrogen bromide produced during bromina capacity equal to or slightly greater than the electron 10 tion in the reaction mixture is reduced. The reduced donor capacity of the cyolobutarene. solubility will increase the quantity of hydrogen bro Suitable organic complexing agents include aliphatic mide that will evolve from the reaction mixture as a gas. alcohols and diols having less than 10 carbon atoms, Since more hydrogen bromide will evolve from the such as methanol, isobutyl alcohol, and ethylene glycol: reaction mixture as a gas, there will be less hydrogen aliphatic polymeric diols having an average molecular 15 bromide in the reaction
Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.414,133 B2 Stössel Et Al
    USOO7414133B2 (12) United States Patent (10) Patent No.: US 7.414,133 B2 Stössel et al. (45) Date of Patent: Aug. 19, 2008 (54) PALLADIUMAND PLATINUM COMPLEXES (58) Field of Classification Search ..................... 546/2: 549/3, 206; 313/504; 257/40: 528/423; (75) Inventors: Philipp Stössel, Frankfurt (DE); Ingrid 526/265 Bach, Bad Soden (DE); Hubert See application file for complete search history. Spreitzer, Viernheim (DE) (56) References Cited (73) Assignee: Merck Patent GmbH U.S. PATENT DOCUMENTS 4,539,507 A 9/1985 VanSlyke et al. (*) Notice: Subject to any disclaimer, the term of this 5,151,629 A 9/1992 VanSlyke patent is extended or adjusted under 35 5,621,131 A 4/1997 Kreuder et al. U.S.C. 154(b) by 637 days. 5,679,760 A 10, 1997 Mullen et al. 5,763,636 A 6/1998 Kreuder et al. (21) Appl. No.: 10/534,173 6,653,438 B1 1 1/2003 Spreitzer et al. 2004/O1384.55 A1 7/2004 Stossel et al. (22) PCT Filed: Nov. 4, 2003 FOREIGN PATENT DOCUMENTS EP O 707 O2O 4f1996 (86). PCT No.: PCT/EPO3/12279 EP O 842 208 5, 1998 EP O 894 107 2, 1999 S371 (c)(1), EP 1 O28 136 8, 2000 (2), (4) Date: May 6, 2005 EP 1 191 613 3, 2002 EP 1238981 9, 2002 WO WO-92, 18552 10, 1992 (87) PCT Pub. No.: WO2004/041835 WO WO-O2, 15645 2, 2000 WO WO-OO.22026 4/2000 PCT Pub. Date: May 21, 2004 WO WO-O2/O68435 9, 2002 (65) Prior Publication Data Primary Examiner P.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,388,135 B1 L0chtman Et Al
    USOO6388135B1 (12) United States Patent (10) Patent No.: US 6,388,135 B1 L0chtman et al. (45) Date of Patent: May 14, 2002 (54) PREPARATION OF 4-BROMOANILINE WO WO 98/31681 7/1998 DERVATIVES WO WO 99/58509 11/1999 (75) Inventors: Rene Lochtman, Mannheim; Michael OTHER PUBLICATIONS Keil, Freinsheim; Joachim Gebhardt, Wachenheim; Michael Rack, Miller et al. “Methoden Der Organischen Chemie' Band Heidelberg; Wolfgang von Deyn, V/4 (1960) pp. 240–242 & 274-249. Neustadt, all of (DE) (73) Assignee: BASF Aktiengesellschaft, Primary Examiner Samuel Barts Ludwigshafen (DE) (74) Attorney, Agent, or Firm-Keil & Weinkauf (*) Notice: Subject to any disclaimer, the term of this (57) ABSTRACT patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. A process for preparing 4-bromoaniline derivatives of the formula I (21) Appl. No.: 09/894,006 (22) Filed: Jun. 29, 2001 Related U.S. Application Data Br R2 (60) Provisional application No. 60/219,410, filed on Jul. 20, 2000. (30) Foreign Application Priority Data Jun. 30, 2000 (DE) ......................................... 10O3O 975 where: (51) Int. Cl." .............................................. C07C 209/00 (52) U.S. Cl. ....................... 564/412; 548/240; 548/247; R" is C1-Co-alkyl, C-C-haloalkyl, C1-Co-alkoxy, 558/418 C-C-haloalkoxy, C-C-cycloalkyl, halogen (58) Field of Search .......................... 564/412; 548/240, R is C-C-alkyl, C-C-alkoxy, Ca-Cs-cycloalkyl, 548/247; 558/418 C-C-alkenyl, cyano or a heterocyclic radical is described. (56) References Cited FOREIGN PATENT DOCUMENTS CA 22783.31 7/1998 30 Claims, No Drawings US 6,388,135 B1 1 2 PREPARATION OF 4-BROMOANILINE which comprises reacting a compound of the formula II DERVATIVES II R1 The present application claims priority of prior provi sional application Serial No.
    [Show full text]
  • Reactive Polymers in Organic Synthesis; Ortho- Benzoquinone and Ortho-Dihydroxyphenyl Derived Polymer Reagents
    Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 1975 Reactive Polymers in Organic Synthesis; Ortho- Benzoquinone and Ortho-Dihydroxyphenyl Derived Polymer Reagents. Dwight Crawford Kaufman Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Kaufman, Dwight Crawford, "Reactive Polymers in Organic Synthesis; Ortho-Benzoquinone and Ortho-Dihydroxyphenyl Derived Polymer Reagents." (1975). LSU Historical Dissertations and Theses. 2838. https://digitalcommons.lsu.edu/gradschool_disstheses/2838 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. INFORMATION TO USERS This material was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image.
    [Show full text]
  • Synthesis of 5-Substituted 7-Azaindoles and 7-Azaindolines
    (19) & (11) EP 1 633 750 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 471/04 (2006.01) 01.12.2010 Bulletin 2010/48 (86) International application number: (21) Application number: 04717703.5 PCT/GB2004/000946 (22) Date of filing: 05.03.2004 (87) International publication number: WO 2004/078757 (16.09.2004 Gazette 2004/38) (54) SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES SYNTHESE VON 5-SUBSTITUIERTEN 7-AZAINDOLEN UND 7-AZAINDOLINEN SYNTHÈSE DE 7-AZAINDOLES ET 7-AZAINDOLINES SUBSTITUÈS EN POSITION 5 (84) Designated Contracting States: • BHATIA, G., AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Eisai London Research Labs. Ltd. HU IE IT LI LU MC NL PL PT RO SE SI SK TR London WC1E 6BT (GB) (30) Priority: 06.03.2003 GB 0305142 (74) Representative: Crooks, Elizabeth Caroline et al Kilburn & Strode LLP (43) Date of publication of application: 20 Red Lion Street 15.03.2006 Bulletin 2006/11 London WC1R 4PJ (GB) (73) Proprietor: Eisai R&D Management Co., Ltd. (56) References cited: Tokyo 112-8088 (JP) WO-A-03/000688 US-A- 5 705 515 (72) Inventors: •PI-TAICHOU, ET AL.: "Excited-State Amine- Imine • GRACZYK, P., Double Proton Transfer in 7-Azaindoline" J. Eisai London Research Labs. Ltd. PHYS. CHEM. B, vol. 104, 2000, pages 7818-7829, London WC1E 6BT (GB) XP002280766 • KHAN, A., • SANDERSON, P. E. J.; ET AL.: "Azaindoles: Eisai London Research Labs. Ltd. Moderately Basic P1 Groups for Enhancing the London WC1E 6BT (GB) Selectivity of Thrombin Inhibitors" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol.
    [Show full text]
  • Identification of 1,5-Naphthyridine Derivatives As a Novel Series of Potent and Selective TGF-Â Type I Receptor Inhibitors
    4494 J. Med. Chem. 2004, 47, 4494-4506 Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-â Type I Receptor Inhibitors Franc¸oise Gellibert,*,† James Woolven,‡ Marie-He´le`ne Fouchet,† Neil Mathews,§,| Helen Goodland,| Victoria Lovegrove,| Alain Laroze,† Van-Loc Nguyen,† Ste´phane Sautet,† Ruolan Wang,⊥ Cheryl Janson,#,× Ward Smith,∇,× Gae¨l Krysa,X Vale´rie Boullay,X Anne-Charlotte de Gouville,X Ste´phane Huet,X and David Hartley| Departments of Medicinal Chemistry and Biology, GlaxoSmithKline, 25-27 Avenue du Que´bec, 91951 Les Ulis, France, Discovery Research, Computational and Structural Science, and Department of Medicinal Chemistry, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom, Discovery Research, Assay Development and Compound Profiling, GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709, and Discovery Research, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 Received January 30, 2004 Optimization of the screening hit 1 led to the identification of novel 1,5-naphthyridine aminothiazole and pyrazole derivatives, which are potent and selective inhibitors of the transforming growth factor-â type I receptor, ALK5. Compounds 15 and 19, which inhibited ALK5 autophosphorylation with IC50 ) 6 and 4 nM, respectively, showed potent activities in both binding and cellular assays and exhibited selectivity over p38 mitogen-activated protein kinase. The X-ray crystal structure of 19 in complex with human ALK5 is described, confirming the binding mode proposed from docking studies. Introduction Chart 1 Transforming growth factor (TGF-â) is a pluripotent cytokine involved in a variety of biological processes such as development, cell growth, differentiation, cell adhesion, migration, extracellular matrix (ECM) deposi- tion, and immune response regulation.1 This cytokine regulates not only the ECM deposition in response to tissue injury, thus contributing to the healing process, the GS domain.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.652,137 B2 Graczyk Et Al
    USOO7652137B2 (12) United States Patent (10) Patent No.: US 7.652,137 B2 Graczyk et al. (45) Date of Patent: Jan. 26, 2010 (54) SYNTHESIS OF 5 SUBSTITUTED WO WO-99,51233 10, 1999 7-AZANDOLES AND 7-AZANDOLINES WO WO-00,26210 5, 2000 WO WO-00,26211 5, 2000 (75) Inventors: Piotr Pawel Graczyk, London (GB); WO WO-OO,35909 6, 2000 Afzal Khan, London (GB); Gurpreet WO WO-00, 35921 A1 6, 2000 Singh Bhatia, London (GB) WO WO-OOf 43393 T 2000 WO WO-OO,56710 9, 2000 (73) Assignee: Eisai R & D Management Co., Ltd. WO WO-00,64449 11, 2000 (JP) WO WO-OOf 64872 11, 2000 WO WO-01/12609 2, 2001 (*) Notice: Subject to any disclaimer, the term of this WO WO-O 1/47922 T 2001 patent is extended or adjusted under 35 WO WO-01/49288 T 2001 U.S.C. 154(b) by 450 days. WO WO-O2/10137 2, 2002 WO WO-O2, 16359 2, 2002 (21) Appl No.: 10A548.162 WO WO-O2/O81475 10, 2002 y x- - - 9 WO WO-03/028724 4/2003 (22) PCT Filed: Mar. 5, 2004 WO WO-03/082868 10, 2003 WO WO-03/082869 10, 2003 (86). PCT No.: PCT/GB2OO4/OOO946 WO WO-2004/O16609 2, 2004 WO WO-2004/O16610 2, 2004 S 371 (c)(1) WO WO-2004/078756 9, 2004 (2), (4) Date: Mar. 13, 2006 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2004/078757 Denmarket al., “Convergence of Mechanistic Pathways in the Pal PCT Pub. Date: Sep.
    [Show full text]
  • Total Synthesis of Ferrugine and Synthetic Studies Towards Ferruginine and Stemofoline
    Total Synthesis of Ferrugine and Synthetic Studies Towards Ferruginine and Stemofoline by Shamim Ahmed A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY School of Chemistry ( University of Birmingham August 2009 1 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Acknowledgements Firstly, I would like to acknowledge my supervisor Dr. Richard Grainger for his continued support and endless guidance throughout my PhD. In particular, I am grateful to him for making me believe in myself during the good, the bad and the ugly times. I am forever grateful to my special wife Nilupa for her everlasting enthusiasm, encouragement, guidance and the level of support received throughout this tough process. I would also like to express my gratitude to the past and present group members such as Luke, Katia, Emma, Bhaven, Tyrone and Benedicte for their support and entertainment over the last few years. I am also grateful to the analytical facility for their assistance, in particular Dr Neil Spencer for NMR, Pete Ashton, and Nick May for mass spectrometry and Dr Benson Kariuki for X-Ray crystallography.
    [Show full text]
  • Drug Discovery and Development
    DRUG DISCOVERY AND DEVELOPMENT Volume 2: Drug Development Edited by MUKUND S. CHORGHADE DRUG DISCOVERY AND DEVELOPMENT DRUG DISCOVERY AND DEVELOPMENT Volume 2: Drug Development Edited by MUKUND S. CHORGHADE Copyright © 2007 by John Wiley & Sons, Inc. All rights reserved. Published by John Wiley & Sons, Inc., Hoboken, New Jersey. Published simultaneously in Canada. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifi cally disclaim any implied warranties of merchantability or fi tness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation.
    [Show full text]